使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, ladies and gentlemen. Welcome to the GE HealthCare Second Quarter 2023 Earnings Conference Call. My name is Olivia and I'll be your conference coordinator today. As a reminder, this conference is being recorded. I would now like to turn the program over to your host for today's conference, Carolynne Borders, Chief Investor Relations Officer. please proceed.
各位女士、先生,大家好。歡迎參加 GE HealthCare 2023 年第二季財報電話會議。我是 Olivia,今天將擔任會議協調人。提醒各位,本次會議將被錄音。現在我想把會議交給今天的主持人——投資人關係長 Carolynne Borders。請開始。
Carolynne Borders - Chief IR Officer
Carolynne Borders - Chief IR Officer
Thanks, Olivia. Welcome to GE HealthCare's Second Quarter 2023 Earnings Call. I'm joined by our President and CEO, Peter Arduini; and our Vice President and CFO, Jay Saccaro. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website.
謝謝你,Olivia。歡迎各位參加 GE HealthCare 2023 年第二季財報電話會議。我與我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Jay Saccaro 一同出席。我們在電話會議中的發言將同時包含 GAAP 與非 GAAP 的財務結果。GAAP 與非 GAAP 指標之間的調節表可在今日新聞稿以及我們網站上的簡報投影片中查閱。
During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties.
在本次電話會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們目前的觀點。如同我們向 SEC 提交的文件所述,實際結果可能因風險與不確定性而出現重大差異。
With that, I'll hand the call over to Peter.
接下來,我把電話交給 Peter。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Thanks, Carolynne. First, let me welcome Jay who's joining us for his first earnings call with GE HealthCare. Since he arrived last month, he's hit the ground running to immerse himself in our business and has been meeting with our global teams. You'll hear more from Jay shortly.
謝謝你,Carolynne。首先,讓我歡迎 Jay——他將與我們一起參加他在 GE HealthCare 的第一場財報電話會議。自上個月加入以來,他迅速投入工作,深入了解我們的業務,並與全球團隊會面。稍後各位會聽到 Jay 的更多分享。
Now let's look at our results for the second quarter. We delivered strong performance with 9% year-over-year organic revenue growth. This was driven by strong demand for NPIs and the continued value that we bring to our customers. We were also pleased to see global demand improve sequentially, delivering 6% orders growth in the second quarter, up from 3% in the first quarter.
現在來看我們第二季的業績。我們交出強勁表現,有機營收年增 9%。這主要受惠於 NPI 的強勁需求,以及我們持續為客戶帶來的價值。我們也很高興看到全球需求較前一季改善,第二季訂單成長 6%,高於第一季的 3%。
We're encouraged by health care providers' continued investment globally in capacity to improve patient care and productivity. Volume remains strong for surgical procedures, which drives demand for imaging, services and surgical equipment. In the U.S., customers are investing in products to improve productivity and enhance overall competitiveness. In the rest of the world, we're seeing solid demand in hospitals and in buying behaviors associated with increased procedures as well as the need for more productivity to address labor constraints.
我們對全球醫療服務提供者持續投資擴充產能、以提升病患照護與生產力感到鼓舞。外科手術量仍然強勁,帶動影像、服務與外科設備的需求。在美國,客戶正投資於提升生產力並強化整體競爭力的產品。在世界其他地區,我們看到醫院需求穩健,採購行為也與手術量增加相關,同時為因應人力限制而需要更高生產力。
We've made good progress on our operating priorities, including increased discipline utilizing lean as a management capability and rigor in areas such as variable cost productivity. This resulted in a 14.8% adjusted EBIT margin, which was an improvement of 70 basis points from Q1. Adjusted EBIT margins were down slightly year-over-year on a stand-alone basis as we continue to invest in the business, with R&D spending up 16% year-over-year in the second quarter.
我們在營運優先事項上取得良好進展,包括更有紀律地將精實(lean)作為管理能力,以及在變動成本生產力等領域的嚴謹執行。這使調整後 EBIT 利潤率達到 14.8%,較第一季提升 70 個基點。以獨立公司口徑來看,調整後 EBIT 利潤率年比略降,因我們持續投資於業務;第二季研發支出年增 16%。
Some areas where we've invested include photon counting, next-gen MR and artificial intelligence optimized interventional cardiology. We're also further developing machine learning capabilities across all modalities to build interoperable ecosystems of devices and applications. We expect our investments to deliver value for our customers while laying the groundwork for the advancement of precision care.
我們投資的領域包括光子計數、下一代 MR,以及以人工智慧優化的介入性心臟病學。我們也在所有成像模態上進一步發展機器學習能力,以建立可互通的設備與應用生態系。我們預期這些投資將為客戶創造價值,同時為精準照護的推進奠定基礎。
Turning to capital allocation. We're focused on pursuing a balanced strategy with the goal of creating value for shareholders. This includes investing organically, acting on the right inorganic opportunities, deleveraging over the near term and initiating a dividend.
接著談資本配置。我們專注於推動均衡策略,以創造股東價值為目標。這包括有機投資、把握合適的非有機機會、在短期內去槓桿,以及啟動股利發放。
With markets improving globally and strong execution in the first half of 2023, we have confidence in our ability to deliver on the full year. As a result, we're raising our full year guidance range for organic revenue growth by 1 percentage point and $0.10 in adjusted EPS at the midpoint. Jay will now take you through our financials. Jay?
隨著全球市場改善,以及 2023 年上半年強勁的執行力,我們對達成全年目標充滿信心。因此,我們將全年有機營收成長指引區間上調 1 個百分點,並將調整後 EPS 的中位數上調 0.10 美元。接下來由 Jay 帶各位回顧財務表現。Jay?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Thanks, Pete. Let me start by saying that I'm thrilled to be here at GE HealthCare at such an exciting time for the company. In particular, I've been really impressed with our team and the collaborative culture across the globe. I'm looking forward to being part of this collaboration and helping to drive our innovation and growth goals, which will ultimately deliver value to our customers and shareholders.
謝謝你,Pete。首先我要說,在公司如此令人振奮的時刻加入 GE HealthCare,我感到非常興奮。尤其令我印象深刻的是我們的團隊,以及遍布全球的協作文化。我期待成為這份協作的一員,並協助推動我們的創新與成長目標,最終為客戶與股東創造價值。
Turning to our financial performance. For the second quarter of 2023, revenues of $4.8 billion increased 7% year-over-year and grew 9% organically. This was driven by strong product growth. As Pete mentioned, organic orders were up 6% year-over-year. We've decided to include this metric going forward as we believe it provides important information regarding demand and our future growth. Book-to-bill improved to 1.04x versus 1.01x in the first quarter of 2023. Our total backlog continues to be healthy at $18.4 billion.
接著看我們的財務表現。2023 年第二季營收為 48 億美元,年增 7%,有機成長 9%,主要由強勁的產品成長帶動。如 Pete 所提到,有機訂單年增 6%。我們決定未來持續揭露此指標,因為我們相信它能提供關於需求與未來成長的重要資訊。出貨比(book-to-bill)提升至 1.04 倍,高於 2023 年第一季的 1.01 倍。我們的總積壓訂單(backlog)仍維持健康水準,達 184 億美元。
On a stand-alone basis, second quarter adjusted EBIT margin improved 70 basis points sequentially, with progress on price, delivery and productivity. However, it was down 10 basis points year-over-year due to inflation and R&D and commercial investments. Adjusted EBIT margin of 14.8% decreased 120 basis points year-over-year as price, productivity and volume benefits were offset by inflation and planned investments. Note that this decline was primarily driven by standalone costs that we did not have in 2022. It was also impacted by a challenging comparator versus the second quarter of 2022, when we delivered an adjusted EBIT margin of 16%. The result last year included mix benefits with increased sales in higher-margin services versus products, given supply constraints.
以獨立公司口徑來看,第二季調整後 EBIT 利潤率較前一季提升 70 個基點,反映在價格、交付與生產力方面的進展。然而,由於通膨以及研發與商業投資,年比下降 10 個基點。調整後 EBIT 利潤率 14.8% 年比下降 120 個基點,因價格、生產力與銷量帶來的效益被通膨與計畫性投資所抵銷。請注意,這一下降主要由 2022 年並不存在的獨立公司成本所致。同時也受到 2022 年第二季較具挑戰性的比較基期影響,當時我們的調整後 EBIT 利潤率為 16%。去年結果包含組合效益:在供應受限下,高毛利服務的銷售占比相對產品提高。
Adjusted EPS was $0.92, up 12% versus prior year on a stand-alone basis, driven by our strong top line growth in the quarter but down 20% year-over-year due to interest expense. Free cash flow was down year-over-year due to incremental interest and pension payments associated with our spin, which I'll discuss in greater detail shortly.
調整後 EPS 為 0.92 美元;以獨立公司口徑來看,較去年同期成長 12%,主要受惠於本季強勁的營收成長,但因利息費用影響,年比下降 20%。自由現金流年比下降,原因是與分拆相關的額外利息與退休金支付增加;我稍後會更詳細說明。
Moving to revenue performance. We grew 9% organically year-over-year. FX was a headwind of 2% to revenue growth. On a reported basis, product revenues increased 11% year-over-year, driven by strong procedural demand. Service revenue grew 1%, which was impacted by foreign exchange. We continue to expect our product growth to translate to service growth in coming quarters as service contracts do lag new product sales.
接著看營收表現。我們的有機營收年增 9%。匯率對營收成長造成 2% 的逆風。以報表口徑計,產品營收年增 11%,主要由強勁的手術量需求帶動。服務營收成長 1%,受到匯率影響。我們仍預期產品成長將在未來幾季轉化為服務成長,因為服務合約通常會落後於新產品銷售。
All regions posted strong sales growth, including in China, where revenue growth was in the double digits. And we expect continued momentum in the third quarter as China continues to prioritize improved health care access.
所有地區都繳出強勁的銷售成長,包括中國在內的營收成長達到雙位數。我們預期第三季動能將持續,因為中國仍持續優先推動提升醫療可近性。
Let's move to margin performance for the quarter. While EBIT margin was down slightly year-over-year on a stand-alone basis as we invest in future innovation, we remain focused on driving margin expansion through operational initiatives and with progress on our separation. During the second quarter, volume increased in all segments and regions. We had positive sales price for the quarter with growth in all segments. We also benefited from AI-powered new product introductions at higher margins. We've made progress on our lean productivity initiatives, with logistics being the main outperformer as a result of improving rates and shifting delivery from air to sea.
接著看本季的利潤率表現。雖然以獨立公司口徑來看,因我們投資於未來創新,EBIT 利潤率年比略降,但我們仍專注於透過營運措施以及分拆進展來推動利潤率擴張。第二季所有事業部與地區的銷量皆增加。本季銷售價格為正向,且各事業部均有成長。我們也受惠於以 AI 驅動的新產品推出,帶來較高的利潤率。我們在精實生產力計畫上取得進展,其中物流表現最為突出,主要因運價改善以及將交付方式由空運轉為海運。
We also saw a decrease in spot buys. Enhancing our productivity efforts gives us visibility into future cost savings. In addition, we're making real progress reducing our SKU count to simplify our portfolio and focus on higher-margin products.
我們也看到現貨採購(spot buys)減少。強化生產力工作讓我們能更清楚掌握未來的成本節省。此外,我們在降低 SKU 數量方面也取得實質進展,以簡化產品組合並聚焦於較高毛利的產品。
On the separation side, we're very much on track with planned exits of TSAs, with approximately 100 exited to date. For instance, we continue to rationalize our IT services and applications to a fit-for-purpose model and we're progressing towards outsourcing certain activities previously performed in-house. Across the organization, we're focused on optimizing G&A by reducing our real estate footprint, our IT costs and other functional expenses.
在分拆方面,我們按計畫退出 TSA(過渡服務協議),目前已退出約 100 項。例如,我們持續將 IT 服務與應用精簡為符合目的(fit-for-purpose)的模式,並推進將先前由內部執行的部分活動外包。在整個組織中,我們專注於透過縮減不動產占用面積、降低 IT 成本及其他職能費用來最佳化 G&A(一般與行政費用)。
That being said, we expect the benefit of many of these changes in 2024 and beyond. As a public company, we're incurring approximately $200 million of recurring stand-alone costs annually that are now impacting our segment EBIT margin rates. These costs are generally allocated based on revenue and equate to roughly 100 basis points of margin headwind for each segment. Overall, we're pleased with the progress we've made in the first half of 2023 and we have line of sight to expand margins going forward through our focused actions.
儘管如此,我們預期其中許多變革的效益將在 2024 年及之後顯現。作為一家上市公司,我們每年產生約 2 億美元的經常性獨立公司成本,現已影響各事業部的 EBIT 利潤率水準。這些成本通常按營收分攤,約相當於各事業部利潤率 100 個基點的逆風。整體而言,我們對 2023 年上半年的進展感到滿意,並且已清楚看到透過聚焦行動在未來推動利潤率擴張的路徑。
Now let's discuss our segments. Turning first to Imaging. We saw strong revenue growth, up 9% year-over-year, driven by molecular imaging CT and MR. We saw supply chain fulfillment improvements, stable demand in the past few quarters, revenues from new products and also pricing initiatives positively impact results. Overall, imaging demand is healthy, supporting top line growth.
現在讓我們討論各事業部。先看影像(Imaging)。在分子影像、CT 與 MR 的帶動下,我們看到營收年增 9% 的強勁成長。我們看到供應鏈履約改善、過去幾季需求穩定、新產品帶來的營收,以及定價措施也對結果產生正面影響。整體而言,影像需求健康,支撐營收成長。
Segment EBIT margin declined 190 basis points year-over-year. We made progress versus last year on productivity, volume and price, though it was more than offset by inflation from prior year purchases and planned investments. Importantly, margins improved 290 basis points on a sequential basis.
事業部 EBIT 利潤率年減 190 個基點。相較去年,我們在生產力、銷量與價格方面有所進展,但先前年度採購所帶來的通膨影響與既定投資計畫的影響更大,因而抵銷了上述改善。重要的是,利潤率按季改善 290 個基點。
Turning to Ultrasound. We generated organic revenue growth of 3% year-over-year following several quarters of strong revenue growth, reflecting significantly high backlog and fulfillment. Revenue growth in the second quarter was driven by cardiovascular and women's health. This included new product launches with AI capabilities aimed at driving improved efficiency and patient outcomes. Segment EBIT margin of 22.8% was down 380 basis points year-over-year, primarily due to planned investments. Productivity and price more than offset inflation. Ultrasound margin performance reflects our investment ramp in new product introductions such as advanced probe technology, products with more digital capabilities and ultrasound-guided surgical navigation.
接著看超音波(Ultrasound)。在連續數季營收強勁成長之後,本季有機營收年增 3%,反映出顯著偏高的積壓訂單與履約交付。第二季的營收成長主要由心血管與女性健康帶動,其中包括具備 AI 能力的新產品上市,旨在提升效率與病患治療成效。事業部 EBIT 利潤率為 22.8%,年減 380 個基點,主要因既定投資所致。生產力與價格的正面影響已足以抵銷通膨。超音波利潤率表現反映我們在新產品導入上的投資加速,例如先進探頭技術、更高數位化能力的產品,以及超音波導引手術導航。
We also have inorganic investment with Caption Health, an artificial intelligence health care leader that creates clinical applications to aid in early disease detection using ultrasound. We've added resources in our commercial organization for increased visibility and capture rate. We continue to focus on our market leadership position, expanding visibility globally and increasing China localization. We're excited about the growth opportunities in this business as we innovate and deliver differentiating technologies to the market.
我們也透過 Caption Health 進行非有機投資;Caption Health 是人工智慧醫療領導者,利用超音波打造臨床應用,以協助早期疾病偵測。我們在商業組織中增加資源,以提升能見度與取得率。我們持續聚焦市場領導地位,擴大全球能見度並提升中國在地化。我們對此業務的成長機會感到振奮,因為我們持續創新並向市場提供具差異化的技術。
Moving to Patient Care Solutions. Organic revenue was up 9% year-over-year, driven by price and volume. We were able to fulfill more backlog with an improved supply chain. Revenue was also driven by new product launches and our backlog remains robust. PCS margins decreased by 50 basis points compared to the second quarter last year, driven by inflation and planned investments, which offset price, productivity and volume growth. We're investing in a digital future across PCS. And in particular, we're excited about the monitoring new products launching in the next few quarters, which we expect will contribute to volume growth.
接著看病患照護解決方案(Patient Care Solutions)。有機營收年增 9%,由價格與銷量帶動。隨著供應鏈改善,我們得以履約更多積壓訂單。營收亦受新產品上市帶動,且我們的積壓訂單仍然強勁。PCS 利潤率較去年第二季下降 50 個基點,主要由通膨與既定投資所致,抵銷了價格、生產力與銷量成長的正面影響。我們正於 PCS 全面投資數位化未來。特別是,我們對未來幾季將推出的監測新產品感到期待,預期將有助於帶動銷量成長。
Moving to pharmaceutical diagnostics, we see continued recovery of global elective procedures, which supported strong organic revenue growth this quarter. Top line revenue was up 20% year-over-year, driven by price and the recovery of volume following the China COVID-related plant shutdown in the second quarter of last year. Recall that in the third quarter of last year, customers were purchasing more contrast media to secure supply. And in the fourth quarter of last year, COVID restrictions were lifted in China.
接著看藥品診斷(pharmaceutical diagnostics),我們看到全球選擇性手術持續復甦,支撐本季強勁的有機營收成長。營收年增 20%,由價格帶動,並受惠於銷量復甦;去年第二季中國因 COVID 相關因素導致工廠停工,基期較低。回顧去年第三季,客戶為確保供應而增加採購對比劑;而去年第四季,中國解除 COVID 限制。
Segment EBIT margin of nearly 27% improved 200 basis points year-over-year, driven by pricing actions, productivity and volume. In addition, there were onetime costs in the year ago quarter due to plant shutdown. This was partially offset by raw material inflation and planned investments.
事業部 EBIT 利潤率接近 27%,年增 200 個基點,主要由定價措施、生產力與銷量帶動。此外,去年同期因工廠停工產生一次性成本。本項改善部分被原物料通膨與既定投資所抵銷。
Next, I'll walk through our cash flow performance. The second quarter was impacted by spin-related items, including net stand-alone interest payments of $193 million and $83 million of incremental post-retirement benefit payments, which were not in our 2022 actuals. Excluding these related post spin-related items, free cash flow would have been positive for the second quarter and an increase year-over-year. As a result, we expect 2Q will be our lowest cash flow quarter of the year.
接下來我將說明我們的現金流表現。第二季受到分拆(spin)相關項目影響,包括 1.93 億美元的淨獨立利息支付,以及 8,300 萬美元的額外退休後福利支付,這些在我們 2022 年實際數中並不存在。若排除這些分拆後相關項目,自由現金流在第二季本應為正,且較去年增加。因此,我們預期第二季將是全年現金流最低的一季。
Working capital improved year-over-year, driven by better inventory management. As we've previously noted, we expect substantially higher free cash flow in the second half of the year relative to the first half due to seasonality and higher volume as well as the timing of certain supplier and compensation payments that occur earlier in the year.
營運資金較去年改善,主要由更佳的存貨管理帶動。如我們先前所述,由於季節性與較高銷量,以及部分供應商與薪酬款項在年初支付的時點因素,我們預期下半年自由現金流將顯著高於上半年。
Let's now turn to our outlook. As Pete said, we're raising our full year 2023 guidance for organic revenue growth and adjusted EPS. We now expect organic revenue growth for 2023 in the range of 6% to 8%, an increase from the prior range of 5% to 7%. Our current view is foreign exchange headwinds of less than 1 percentage point for the year. We expect revenue growth in the second half to be in line with our medium-term growth target of mid-single digits. We continue to expect full year adjusted EBIT margin to be in the range of 15% to 15.5%. This represents an expansion of 50 to 100 basis points over a 2022 stand-alone adjusted EBIT margin.
現在談談展望。如 Pete 所說,我們上調 2023 全年有機營收成長與調整後 EPS 指引。我們目前預期 2023 年有機營收成長介於 6% 至 8%,高於先前的 5% 至 7%。我們目前的看法是,全年匯率逆風小於 1 個百分點。我們預期下半年營收成長將符合我們中期目標的中個位數成長。我們仍預期全年調整後 EBIT 利潤率介於 15% 至 15.5%。這代表相較 2022 年獨立口徑(stand-alone)的調整後 EBIT 利潤率擴張 50 至 100 個基點。
We remain focused on driving margin expansion while continuing to innovate and invest in the business to drive long-term growth. We expect to see an increase in adjusted EBIT margin in the second half of the year relative to the first half. As we experience higher volume, we drive productivity benefits and also with the contribution from new product introductions.
我們仍專注於推動利潤率擴張,同時持續創新並投資業務以帶動長期成長。我們預期下半年調整後 EBIT 利潤率將高於上半年。隨著銷量提升,我們將帶動生產力效益,並受惠於新產品導入的貢獻。
In line with seasonality, we expect the fourth quarter adjusted EBIT margin to be the highest of the year while 3Q will be similar to 2Q. We are also raising our full year 2023 adjusted EPS outlook to a range of $3.70 to $3.85, representing 9% to 14% growth versus 2022 stand-alone adjusted EPS of $3.38. This compares to our previous range of $3.60 to $3.75.
依季節性而言,我們預期第四季調整後 EBIT 利潤率將為全年最高,而第三季將與第二季相近。我們也上調 2023 全年調整後 EPS 展望至 3.70 至 3.85 美元,較 2022 年獨立口徑調整後 EPS 3.38 美元成長 9% 至 14%。相較之下,我們先前的區間為 3.60 至 3.75 美元。
We continue to expect free cash flow conversion to be 85% or more for the full year, with stronger free cash flow generation in the second half. Our cash flow outlook assumes that legislation requiring R&D capitalization for tax purposes is repealed or deferred beyond 2023. The free cash flow impact of this legislation would represent up to 10 percentage points of free cash flow conversion for the year.
我們仍預期全年自由現金流轉換率為 85% 或以上,且下半年自由現金流產生將更強勁。我們的現金流展望假設:要求就稅務目的將研發(R&D)資本化的立法將被廢止,或延後至 2023 年之後。該立法對自由現金流的影響,全年最多可能相當於自由現金流轉換率的 10 個百分點。
Now I'll hand the call back to Pete.
現在我把電話交回給 Pete。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Thanks, Jay. Before turning to Q&A, I want to touch on a few exciting areas that GE HealthCare is focused on to address patient and customer needs. In imaging this quarter, we announced 2 deep learning artificial intelligence technologies, Precision DL and Sonic DL. Precision DL is available on our Omni Legend PET CT and enables faster scan times and smaller lesion detectability. Sonic DL leverages capabilities from our Air Recon DL MR platform and acquires high-quality MR images up to 12x faster than conventional methods.
謝謝,Jay。在進入問答之前,我想談談 GE HealthCare 為滿足病患與客戶需求而聚焦的幾個令人振奮的領域。本季在影像方面,我們宣布兩項深度學習人工智慧技術:Precision DL 與 Sonic DL。Precision DL 可用於我們的 Omni Legend PET CT,能縮短掃描時間並提升對較小病灶的可偵測性。Sonic DL 運用我們 Air Recon DL MR 平台的能力,可用比傳統方法快達 12 倍的速度取得高品質 MR 影像。
By enabling imaging with a single heartbeat, it reduces the need for repetitive patient breath holds making MRI more accessible for cardiac patients. In ultrasound, we introduced the world's first and most compact mini 3D transesophageal echocardiogram probe, designed for pediatric cardiology. It's 57% smaller than an adult probe and it provides access to real-time 3D imaging for children who could not tolerate an adult size probe. This innovative probe technology is an example of our investment and leadership position in ultrasound.
透過單次心跳即可完成成像,它降低病患反覆憋氣的需求,使 MRI 對心臟病患更易取得。在超音波方面,我們推出全球首款且最小巧的迷你 3D 經食道心臟超音波探頭,專為小兒心臟科設計。其尺寸比成人探頭小 57%,可讓無法耐受成人尺寸探頭的兒童取得即時 3D 影像。這項創新的探頭技術展現了我們在超音波領域的投資與領導地位。
We continue to invest in commercial capabilities and expand further into adjacent and new markets such as point-of-care and handheld ultrasound.
我們持續投資商業能力,並進一步擴展至相鄰與新市場,例如即時照護(point-of-care)與手持式超音波。
In PCS, we're investing in monitoring solutions for critical care and acute patients. The introduction of CARESCAPE Canvas gives us a platform to build on for years to come and with Portrait Mobile being the newest addition on the platform. Portrait Mobile enables care teams to monitor the unmonitored by shifting the paradigm from periodic spot checks to continuous monitoring, freeing the patient from the bed while continuously monitoring for signs of patient decline.
在 PCS 方面,我們正投資用於重症照護與急性病患的監測解決方案。CARESCAPE Canvas 的推出為我們提供可多年持續發展的平台,而 Portrait Mobile 則是該平台最新加入的產品。Portrait Mobile 讓照護團隊能監測原本未被監測的病患,將模式從定期抽查轉為連續監測,使病患不必受限於病床,同時持續監測病況惡化的徵兆。
These are our first major introductions in monitoring in recent years and create an opportunity for installed base upgrades as well as new growth.
這些是我們近年來在監測領域的首批重大產品導入,並為既有裝機基礎的升級以及新的成長帶來機會。
In PDx, we announced the National Comprehensive Cancer Network guidelines, now recommend the use of FES PET imaging agent for estrogen receptor positive disease for patients. Cerianna is the first and only U.S. FDA-approved imaging agent to help clinicians assess reoccurring or metastatic breast cancer. The benefit of Cerianna is that it provides a whole-body view of estrogen receptor positive lesions in 1 exam. We're encouraged that the addition of Cerianna to the NCCN guidelines will increase this adoption.
在 PDx 方面,我們宣布美國國家綜合癌症網絡(NCCN)指引現已建議,對雌激素受體陽性疾病患者使用 FES PET 影像顯影劑。Cerianna 是美國首個且唯一獲 FDA 核准的影像顯影劑,可協助臨床醫師評估復發或轉移性乳癌。Cerianna 的優勢在於可在一次檢查中提供全身雌激素受體陽性病灶的視圖。我們樂見 Cerianna 納入 NCCN 指引將提升其採用率。
Turning to recent news about advancements in Alzheimer's disease therapies. Many of you heard about the FDA's recent approval of lecanemab and all other promising models -- molecules in the pipeline that have the potential to provide millions of patients high-quality quality of life, if diagnosed and treated early. Before now, the only option was to fundamentally treat the symptoms. As these new therapies become more widely available, there's a need for precise and noninvasive imaging and digital solutions, which we're well positioned to deliver on.
接著談談近期關於阿茲海默症治療進展的新聞。許多人都聽說 FDA 近期核准 lecanemab,以及其他所有具前景的模式——研發管線中的分子——若能及早診斷並治療,這些分子有潛力為數百萬名患者帶來高品質的生活品質。在此之前,唯一的選項基本上是治療症狀。隨著這些新療法更廣泛可得,市場對精準且非侵入式的影像與數位解決方案的需求也隨之提升,而我們具備優勢,能夠提供這些方案。
Let me walk you through the opportunities for GE HealthCare. Our technology, including MR and PET scanners and our amyloid imaging agent, Vizamyl, combined with digital solutions, enables us to be a disease state solution provider for our customers. As you can see on the page, these breakthrough therapies will create new market opportunities for us in upfront diagnosis, safety monitoring and follow-up. This approach that we often refer to as D3, which is about smart devices and drugs, a disease state-focused and digital solutions. And is a good example of how we think about care pathways and our evolving role to provide precision care.
我來帶各位看看 GE HealthCare 的機會。我們的技術,包括 MR 與 PET 掃描儀,以及我們的類澱粉蛋白影像顯影劑 Vizamyl,結合數位解決方案,使我們能成為客戶的疾病狀態解決方案供應商。如各位在頁面上所見,這些突破性療法將在前端診斷、安全性監測與追蹤方面,為我們創造新的市場機會。我們常稱之為 D3 的方法,重點在於智慧裝置與藥物、以疾病狀態為核心,以及數位解決方案。這也是我們如何思考照護路徑,以及我們不斷演進、以提供精準照護之角色的良好例子。
While it's still early in the Alzheimer's therapy journey, we remain very optimistic about the benefit for patients and the growth opportunities this will generate for GE HealthCare, as a partner to providers.
雖然阿茲海默症療法的旅程仍在早期階段,但我們對患者所能獲得的效益,以及這將為 GE HealthCare 作為醫療提供者夥伴所帶來的成長機會,仍然非常樂觀。
In summary, we've had many accomplishments since our launch as an independent company and they have set us up for long-term sustainable growth. I'd like to thank our 50,000-plus team members across the globe for their dedication and contributions on our initial phase of growth. I'm pleased with the results we've delivered in the first half, with strong visibility into our second half, supporting our updated outlook for the full year. We're seeing continued solid market demand for our products and services. We're allocating our R&D spend into high-growth areas to drive long-term innovation, while also driving margin improvement actions. And our healthy backlog provides good line of sight through '23 and into '24.
總結來說,自我們以獨立公司身分上市以來已取得許多成果,並為長期可持續成長奠定基礎。我要感謝全球超過 50,000 名團隊成員在我們初期成長階段的投入與貢獻。我對上半年交出的成果感到滿意,且對下半年有很高的能見度,支持我們更新後的全年展望。我們持續看到市場對我們產品與服務的穩健需求。我們將研發支出配置到高成長領域以推動長期創新,同時也推動改善利潤率的行動。而我們健康的訂單積壓(backlog)也讓我們對 2023 年並延伸至 2024 年有良好的可視性。
And with that, we'll open up the call for questions.
接下來,我們將開放提問。
Carolynne Borders - Chief IR Officer
Carolynne Borders - Chief IR Officer
Thank you, Peter. (Operator Instructions). Olivia, can you please open the line?
謝謝你,Peter。(接線員指示)。Olivia,請幫我們開線。
Operator
Operator
Certainly. (Operator Instructions) And our first question coming from the line of Anthony Petrone with Mizuho.
好的。(接線員指示)我們的第一個問題來自 Mizuho 的 Anthony Petrone。
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
And congratulations on a solid 2Q performance here and a positive outlook on the second half. Maybe, Jay, I'll start with you, 1 for you on margins and then I'll hop over to Pete on the comments on Alzheimer's disease. First, Jay, welcome to GE. Look forward to working with you. Maybe to recap on the TSA roll-off and when -- how many TSAs are left? And when do you expect to see leverage gains against those TSAs rolling off at the operating margin level? And I'll have a follow-up for Pete on Alzheimer's disease.
恭喜第二季(2Q)表現穩健,且對下半年展望正向。Jay,我先從你這邊開始,先問一題關於利潤率,接著我再請教 Pete 關於阿茲海默症的評論。首先,Jay,歡迎加入 GE,期待與你共事。想請你回顧一下 TSA 的到期(roll-off)情況——目前還剩多少 TSA?以及你預期在這些 TSA 陸續到期後,營業利潤率層面何時能看到槓桿效益的提升?之後我會再追問 Pete 關於阿茲海默症。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Great. Thank you, Anthony. Appreciate it. So far, from a TSA standpoint, things are very much on track. We have quite a few to exit. In fact, we probably have over 400 TSAs to exit over the next several years, with the vast majority of those exits taking place 18 to 24 months following the spin. But so far, we've exited 100 and it really is setting the stage for our successful transition to a stand-alone public entity. Importantly, about 1/3 of the exits that we've had thus far are related to IT, another -- about half of them are related to facilities. So I would say that there's really good progress on setting ourselves up. And then once we have that in place, we can really start to optimize the long-term footprint, the long-term operations of our company.
很好。謝謝你,Anthony,感謝提問。就 TSA 而言,目前一切都非常按計畫進行。我們還有相當多需要退出。事實上,未來幾年我們可能需要退出超過 400 份 TSA,而其中絕大多數的退出會發生在分拆(spin)後 18 到 24 個月。但到目前為止,我們已退出 100 份,這確實為我們成功轉型為獨立上市公司奠定了基礎。重要的是,截至目前約三分之一的退出與 IT 相關,另外——約一半與設施相關。所以我會說,我們在為自身打底方面進展良好。等這些到位後,我們就能真正開始優化公司的長期據點配置與長期營運。
What I mean by that and in the prepared remarks, I made a statement about our IT area. IT is an area where we have tremendous optimization opportunities. I just spent a few days with the IT team walking through many of those opportunities, things like moving to the cloud many of the servers that are currently hosted, things like rationalizing the application service providers, all of those will give us a multiyear tailwind in terms of optimization of cost. But the first step is getting to stand-alone. And so, so far, so good on the TSAs. This is going to be a -- this will impact 2024, '25 and '26, more than it does '23 but it's crucial at this stage that we operate effectively as a stand-alone.
我的意思是,在事先準備的講稿中,我提到我們的 IT 領域。IT 是我們擁有巨大優化機會的領域。我剛花了幾天與 IT 團隊一起梳理許多機會,例如把目前託管的許多伺服器移轉到雲端、精簡應用服務供應商等;這些都將在成本優化方面帶來為期多年的順風。但第一步是先達成獨立運作。因此,就 TSA 而言,目前為止一切順利。這將對 2024、2025、2026 的影響大於 2023,但在這個階段,能有效以獨立公司身分運作至關重要。
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
And again, welcome to the team. And then maybe, Pete, just pivoting to the comments on Alzheimer's disease. You referenced LEQEMBI, recently secured an FDA approval here and more recently than that, we've seen CMS actually propose local MACs to cover beta PET scans for beta amyloid plaque. That's a proposal that was put out there about a week ago. So when we take a higher-level look at this demand cycle, is there anything you can sort of book end us on the early views on a TAM opportunity when we consider that there's MR involved here, there's also PET CT several -- at several phases along the patient journey here. So maybe just your early thoughts on when this demand cycle begins and how large it can be for GE?
再次歡迎你加入團隊。接著,Pete,轉到你對阿茲海默症的評論。你提到 LEQEMBI 最近已取得 FDA 核准,而更近期我們也看到 CMS 實際上提議由地方 MACs 承保用於 β 類澱粉蛋白斑塊的 β PET 掃描。這項提案大約是一週前提出的。那麼,從更高層次來看這一波需求循環,當我們考量其中涉及 MR,且在患者旅程的多個階段也會用到 PET CT 時,你能否就 TAM(總可服務市場)機會的早期看法,幫我們做個前後框架?也請談談你對這個需求循環何時開始、以及對 GE 可能有多大的初步想法。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Anthony, thanks for the question. I mean, let me just start out with -- I mean, we're just living in a really fantastic window of time here, where between different therapies are coming up that are going to change patients' lives. And I think it's such a tremendous win for patients, these new drugs are coming out. Look, to bring this forward, as you know, governments (inaudible) CMS with reimbursement, pharma and a company like GE HealthCare working with providers really what it's all about. And I think that's one of the interesting changes here, not only in this disease area but in other areas where we play a significant role in bringing forth these capabilities.
Anthony,謝謝你的問題。我先從——我們正處在一個非常精彩的時間窗口開始談起,因為有不同的療法正在出現,將改變患者的生活。我認為這對患者是非常巨大的勝利,這些新藥正在問世。你也知道,要把這件事推進,需要政府(聽不清)與 CMS 的給付、藥廠,以及像 GE HealthCare 這樣與醫療提供者合作的公司共同努力,這才是重點。我認為這也是一個有趣的變化,不僅在這個疾病領域,在其他我們扮演重要角色、推動這些能力落地的領域亦然。
I think 30%, 40% improvement, some early indications that earlier patients, better improvement gives us pretty strong confidence that these are going to be impactful. Think of us as the company that facilitates, so to speak, kind of the management of the disease. If you think about the last chart that I pulled up in the deck on 14, where we play a screening and assessment role with MR or our PET products, we play a major role in diagnosis with PET and are also radiopharmaceutical imaging tracer, Vizamyl and then actually treatment and monitoring. And in treatment, as you probably know, after each of the injections having an MRI to make sure that there aren't any baseline side effects. And then we think longer-term monitoring to see what is the baseline of the amyloid beta reduction at that point.
我認為 30%、40% 的改善,以及一些早期跡象顯示越早期的患者改善越好,讓我們相當有信心這些療法將會產生影響。你可以把我們視為促成者,某種程度上是協助疾病管理的公司。若你回想我在簡報第 14 頁展示的最後一張圖表,我們透過 MR 或 PET 產品在篩檢與評估上扮演角色;我們也透過 PET 以及放射性藥物影像示蹤劑 Vizamyl 在診斷上扮演重要角色;接著是治療與監測。在治療方面,如你所知,每次注射後都會做 MRI,以確保沒有任何基線副作用。然後我們也認為,長期監測將用來觀察在那個時間點 β 類澱粉蛋白降低的基準狀態。
And that all encompassed with some digital solutions that can make reregistration, that can make integration, make the tool sets much easier outside of an academic setting so that this can work for providers. And so our opportunity is to work with big IDNs as well to help them think through the problem statement that's in front of them, of how do you provide this across rural care, concentrated city care, fleet management. And we think we can help make that happen.
而這一切再搭配一些數位解決方案,可用於重新配準(reregistration)、整合,讓工具組在非學術環境下也更容易使用,使醫療提供者能夠落地。因此,我們的機會在於也與大型 IDN 合作,協助他們思考眼前的問題陳述:如何在偏鄉照護、都會集中式照護、以及設備隊列管理(fleet management)等情境下提供這些服務。我們認為我們能協助促成這件事。
On the size of the opportunity, I think it's a little too early to say. I think it's not a huge opportunity in '23. But if you look over '24, '25, '26, depending on the uptake of the drug, which is going to be heavily tied to a companion diagnostic reimbursement, therapy diagnostic and the follow-on drugs, we believe that this is a pretty profound growth opportunity across the space. But time will tell how that ultimately plays out. The last point I would just make is that we're really the only company that touches all of these areas, MRI, PET MR, PET CT and the radiopharmaceutical tracer. And what's interesting about the radiopharmaceuticals is -- and I think you know this well, is unlike other drugs or a generic where it can be vialed and put on the shelf. This is a product that once it's made, it has a half-life of under 2 hours. So it starts degrading. And we already have a large network in the U.S. and Europe as well to actually distribute these radioactive isotopes.
至於機會的規模,我認為現在下定論還稍早。我認為在 2023 年不會是很大的機會。但若看 2024、2025、2026,取決於藥物的採用速度——而這將高度取決於伴隨診斷的給付、治療診斷以及後續藥物——我們相信這會是整個領域相當深遠的成長機會。但最終如何發展,仍有待時間驗證。最後我想補充的是,我們幾乎是唯一一家涵蓋所有這些領域的公司:MRI、PET MR、PET CT,以及放射性藥物示蹤劑。有趣的是放射性藥物——我想你也很清楚——不同於其他藥物或學名藥可以裝瓶後放在架上;這種產品一旦製成,半衰期不到 2 小時,因此會開始衰變。而我們在美國與歐洲也已建立龐大的網路,用於實際配送這些放射性同位素。
And so as they evolve and they grow with other folks coming into the marketplace, I think that's going to be an interesting opportunity for us to play as well. But I think, in the near term, we'll see how these pieces come together. But we're super optimistic, I think, first for patients and their families; and then second, the opportunity that we can play.
因此,隨著它們演進並成長、也有其他業者進入市場,我認為這將是我們也能參與的一個有趣機會。但我想,在短期內,我們會看看這些拼圖如何整合在一起。不過我們非常樂觀:第一是對病患及其家屬;第二則是我們能夠參與其中的機會。
Operator
Operator
And our next question coming from the line of Ryan Zimmerman with BTIG.
下一個問題來自 BTIG 的 Ryan Zimmerman。
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Congrats on a nice quarter here. I wanted to just talk about the implied order growth and I appreciate you guys including that metric this quarter. I think investors were looking for that. But just the implied order growth. In the back half of the year, you faced some tougher comps, if I'm not mistaken. And how to think about that in relative context to the RPO, which is down maybe about 120 basis points in total?
恭喜本季表現不錯。我想談談隱含的訂單成長,也很感謝你們這一季把這個指標納入揭露,我想投資人一直在找這個。不過就隱含訂單成長而言,下半年你們面臨較嚴峻的比較基期(如果我沒記錯的話)。以及該如何把它放在相對於 RPO 的脈絡下來看?RPO 總體可能下滑了大約 120 個基點?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. Maybe I'll start with a couple of comments and then turn it over to Pete. And overall, we do appreciate your comments in terms of including order growth. We did feel like this was an important metric for us to share. What I would say is, we're pleased with the strong second quarter orders coming in at 6%. I think, for us, we see health care providers continuing to invest globally in capacity to improve patient care. So all of that is very important for us and very -- a critical driver long term. And I would say, as we look at the second half orders growth, for us, we're very focused on kind of driving this mid-single-digit area because it's critical to the long-term model that we have as a company. For us, mid-single-digit growth is something that we're targeting for the next several years. So we're going to continue to drive performance and target that level.
好的。也許我先講幾點,然後再交給 Pete。整體而言,我們也很感謝你對於納入訂單成長指標的評論。我們確實覺得這是我們應該分享的重要指標。我想說的是,我們對第二季訂單強勁、達到 6% 感到滿意。對我們來說,我們看到全球的醫療照護提供者持續投資擴充產能,以改善病患照護。因此這些對我們非常重要,且長期而言是非常——關鍵的驅動因素。我也想說,當我們看下半年訂單成長時,我們非常專注於推動中個位數(mid-single-digit)區間,因為這對我們作為一家公司的長期模型至關重要。對我們而言,中個位數成長是我們未來幾年要達成的目標。因此我們會持續推動績效並以該水準為目標。
What I would say is, as it relates to the backlog, our backlog overall declined a bit. I think it was $19 billion and it declined to $18.4 billion, that's simply related to the fact that revenues grew faster than orders. And so we have an incredibly healthy backlog at this point. We feel quite good about the quality of the backlog as well. So I think that's something that we're going to watch through the rest of the year because it does set up 2024 nicely if we can have a robust backlog in place as we approach Q4. So, so far, so good. There's nothing other than that dynamic of faster revenues than orders that contributed to the decline but we'll continue to watch this. Pete?
我想說的是,就積壓訂單(backlog)而言,我們的積壓訂單整體小幅下降。我想原本是 190 億美元,下降到 184 億美元,這純粹是因為營收成長速度快於訂單。因此目前我們的積壓訂單非常健康。我們也對積壓訂單的品質感到相當放心。我認為這是我們在今年剩餘時間會持續觀察的項目,因為如果在接近第四季時能維持強勁的積壓訂單,將能為 2024 年打下很好的基礎。所以到目前為止一切都不錯。除了營收成長快於訂單這個動態之外,沒有其他因素造成下降,但我們會持續關注。Pete?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes. I mean, Jay, I think you covered it all. I'd just say, Ryan, we were pleased with the performance, obviously, the step-up from Q1. As you know, there's still a little bit of noise in ours and many folks' numbers coming out of COVID and which countries switched at what point in time. But this is about real durable demand that we see particularly in our imaging world and across the board. But I think that's where we're seeing aligned with our other comments about the productivity that those products bring and also the backlogs that exist because of incoming procedures.
是的。我的意思是,Jay,我想你都涵蓋到了。我只想說,Ryan,我們對表現感到滿意,顯然相較第一季有提升。如你所知,從 COVID 走出來後,我們以及許多同業的數字仍有一些雜訊,包含各國在不同時間點切換所造成的影響。但這反映的是我們看到的真實且具持續性的需求,特別是在我們的影像業務領域以及整體各方面。我想這也與我們先前關於這些產品帶來的生產力、以及因為新增檢查程序而存在的積壓量等評論一致。
This is how you diagnose, this is how you plan, surgically guide. So there's strong demand in those aspects. And I would just say, we've talked about our midterm guidance out into the future being mid-single digits revenue growth. And I mean, obviously standpoint here is that we're -- we feel quite good about what the orders funnel is coming in to feed that backlog to set us up for in the coming years.
這些就是你如何診斷、如何規劃、如何在手術中導引。因此在這些面向的需求很強。我也想說,我們談到的中期指引是未來中個位數的營收成長。顯然我們目前的觀點是——我們對訂單管道的流入感到相當有信心,能夠補充積壓訂單,讓我們在未來幾年有良好布局。
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
That's very helpful. And then Jay, for you, I'm looking back at the medium-term margin target from the Capital Markets Day. I think they were high teens to low 20s. And you called out the standalone costs. I assume those were factored in the guidance but just given kind of your early time in the company, maybe you can comment on whether you see those medium-term targets as more achievable, less achievable and just timing around those, if you're comfortable sharing that in terms of EBIT margins?
這很有幫助。接著 Jay,我回頭看資本市場日(Capital Markets Day)提出的中期利潤率目標,我想是高十幾到低二十幾(high teens to low 20s)。你提到了獨立營運成本(standalone costs)。我假設這些已納入指引,但考量你加入公司時間還不長,或許你可以評論一下:你認為這些中期目標更可達成、較不易達成,或是時程上如何?如果你願意分享的話,特別是就 EBIT 利潤率而言。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. Overall, what I would say is, I feel good about the margin targets that the company has put together. From my standpoint, we're a new public company, so there's a lot of opportunity that's simply created by spinning off this enterprise. But then if you look at the drivers that we've laid out, commercial execution, innovation and optimization, there are real opportunities underlying each of these. From a commercial execution standpoint, this idea of disciplined around pricing, it really is embedded in the culture at the company. We've targeted 2% to 3% this year, 1% to 2% going forward. This idea of commercial execution and how we capture the real value that we're providing to health care providers in the products that we sell, I think it's something that's going to continue to bear fruit.
好的。整體而言,我想說我對公司所制定的利潤率目標感到有信心。從我的角度來看,我們是一家新上市公司,因此透過分拆這個企業本身就創造了很多機會。但如果你再看我們列出的驅動因素——商業執行、創新與最佳化——每一項背後都有實質機會。就商業執行而言,對定價保持紀律這個概念,確實已深植於公司文化之中。我們今年的目標是 2% 到 3%,未來則是 1% 到 2%。這種商業執行、以及我們如何在所銷售的產品中捕捉我們為醫療照護提供者所帶來的真正價值,我認為將會持續開花結果。
From an innovation standpoint, I think we collectively are incredibly excited about the innovation opportunities that we have. And frankly, if I were to say, what's the biggest surprise coming in, it's the richness and the depth of the innovation portfolio and this care continuum approach, which is just really remarkable from my perspective. So I'm quite excited about innovation as a driver. And then, finally and I alluded to this a little bit more, there's a lot of low-hanging fruit that we can optimize as we move forward. And that's just true of any new public company. There are real opportunities for us to rethink how we provide IT services and other areas. So there's some great opportunity there.
就創新而言,我認為我們整體對所擁有的創新機會感到非常興奮。坦白說,如果要我說進來後最大的驚喜是什麼,那就是創新產品組合的豐富度與深度,以及這種照護連續體(care continuum)的做法,從我的角度看真的非常了不起。所以我對創新作為驅動因素感到相當興奮。最後,正如我稍早提到的,我們在往前走的過程中有很多「低垂的果實」可以最佳化。這對任何新上市公司都成立。我們在重新思考如何提供 IT 服務以及其他領域方面,確實有實質機會。因此那裡有很好的機會。
So generally speaking, without being specific, I would say I feel quite good about it. The last comment I'd make related to this is another aspect of the culture that's been impressive to me is this lean mindset. And so this idea of how do we get after optimization in our factories, how do we get after optimization in our end-to-end process, I think that's another tool in the toolbox that's going to go a long way to helping us transform the margin of the company.
所以一般來說,在不具體化的前提下,我會說我對此感到相當有信心。最後我想補充的一點是,另一個讓我印象深刻的文化面向是這種精實(lean)的思維。因此,如何在工廠端推動最佳化、如何在端到端流程中推動最佳化,我認為這也是工具箱裡的另一項工具,將在協助我們改善公司利潤率方面發揮很大作用。
Operator
Operator
And our next question coming from the line of Patrick Wood with Morgan Stanley.
下一個問題來自 Morgan Stanley 的 Patrick Wood。
Patrick Wood
Patrick Wood
I'll just keep it to 2 quick ones, hopefully. So the first one, order books, nice plus 6%. I'd love if you could give any more detail pulling apart, whether by modality and imaging or -- we don't need the numbers specifically. I'm just curious as to where you're seeing the biggest strength, either by modality or by region? Just a little bit more color there would be really handy.
我盡量只問兩個簡短問題。第一個是訂單簿,成長 +6% 很不錯。我想請你們再多提供一些拆解細節,例如按影像的不同模態(modality)或——我們不需要具體數字。我只是好奇你們看到最大的強勁動能在哪裡,是按模態還是按區域?如果能多給一點顏色會很有幫助。
And then the second one actually is around the whole AI commentary side of things. Things like scan speed acceleration, obviously, there's implications for the installed base. But is it a function that you can take better pricing and then maybe you get better penetration in the therapeutic areas like cardiac, that means that the installed base remains healthy and large at a better price rather than needing fewer systems to scan the same number of patients, if you see what I mean? So any sense around like whether it's pricing or grow through better, let's say, adoption of radiology in areas where it wasn't previously there, just curious how you see that dynamic?
第二個其實是關於整體 AI 評論的部分。像是掃描速度加速,顯然會對裝機基礎(installed base)有影響。但這是否意味著你們可以取得更好的定價,並且在例如心臟等治療領域獲得更高滲透率,讓裝機基礎以更好的價格維持健康且規模更大,而不是因為同樣數量的病患可以用更少的系統完成掃描——如果你理解我的意思的話?所以你們怎麼看這個動態:是透過定價,或是透過更好的成長——例如在過去放射科採用度較低的領域提升採用——我只是好奇你們怎麼看。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes. So maybe I'll start with the AI piece and then, Jay, if you want to add some color, what we can on the orders front. Look, Patrick, I think the artificial intelligence, obviously, it's affecting all areas within all the economic areas around the world in different ways. I think, in our world in particular, the first levels, what it's helped is actually kind of changing how product is used, making it more straightforward, automating many steps in productivity. So in the case of a institution that's having labor constraints, which you can include almost all, being able to actually automate, which enables more throughput on that given higher labor dollar is a big deal. And so many of our products, we have 42 approved FDA AI-integrated applications that are out there, really one of the leaders in the space, that's been a big deal.
是的。所以也許我先從 AI 的部分開始,然後在訂單方面,Jay 如果你想補充一些我們能分享的內容。Patrick,你看,人工智慧顯然正以不同方式影響全球各地所有經濟領域。我認為在我們這個領域,第一層面的幫助其實是改變產品的使用方式,讓它更直覺,並在生產力上自動化許多步驟。因此,對於面臨人力限制的機構——幾乎可以說所有機構都是——能夠進行自動化、在更高的人力成本下仍能提升單位時間產出(throughput),這是一件大事。我們許多產品目前已有 42 個通過 FDA 核准、整合 AI 的應用,是這個領域的領導者之一,這點帶來了很大的影響。
And what we focused on, I would say, different than maybe some of our competitors is, is not only on the new product but taking it back into the installed base. And why that's so important and it gives us a differentiated value is, if you have 4 of our MRs already and you want to add 2 other new sites, upgrading those MRs with the capability that literally makes them state-of-the-art image quality of today, better than what's out in the marketplace, as well as increases their productivity by 30%, 40% and sometimes 50% throughput, it's a huge deal. And obviously, the ability to upgrade your own systems is only allowed to the manufacturer and then combining that. So that's how -- 1 area that we create significant value. The other area is simplifying kind of the diagnostic process and how that's playing out. And that starts with, honestly, beyond AI, cloud-based computing and enablement of applications for the customers.
而我們所聚焦的,我會說,可能不同於一些競爭對手的是,我們不僅著眼於新產品,還把它帶回到既有裝機基礎中。之所以這麼重要、也讓我們具備差異化價值的是:如果你已經有 4 台我們的 MR,並且想在另外 2 個新據點新增設備,透過升級這些 MR,使其具備能讓影像品質真正達到當今最先進水準、甚至優於市面上產品的能力,同時把生產力提升 30%、40%,有時甚至 50% 的吞吐量,這是非常重大的價值。而且,顯然,能夠升級自家系統的能力只有原廠才被允許,並把這些結合起來。因此,這就是我們創造顯著價值的其中一個領域。另一個領域是簡化診斷流程,以及這件事如何落地展開。這首先從坦白說,超越 AI 的雲端運算,以及為客戶啟用應用程式開始。
And we'll be demonstrating later this year our own store, so to speak, that allows reoccurring revenue for applications and access to them wherever that patient might be within that customer network. And then, longer term, which we're leading to and we'll be demonstrating later this year, is this whole idea of multimodal data integration. And it's a really important aspect of the AI side that if you do have multiple exams or capabilities that you can get assistance in actually interpreting in what they mean and we'll talk more about that. I think that's going to also be an important part of this Alzheimer's opportunity that we have as well as to kind of simplify, again, around a given disease state, how we actually support the case.
而我們將在今年稍晚展示我們自己的「商店」(可以這麼說),讓應用程式能帶來經常性收入,並且讓病患無論位於該客戶網路中的何處,都能存取這些應用。再更長期而言——我們正朝這方向前進,並且也會在今年稍晚展示——是「多模態資料整合」這整個概念。這是 AI 面向中非常重要的一環:如果你確實有多項檢查或能力,你就能在實際解讀其意義時獲得協助,我們之後會再多談。我認為,這也將成為我們阿茲海默症機會的重要部分,同時也能再次在特定疾病狀態周邊簡化我們如何支援個案。
So that's kind of it on the AI front. I think a combination of added productivity and throughput but also new capabilities to think about how you manage a disease state differently.
以上大致就是 AI 方面的內容。我認為,這是提升生產力與吞吐量的組合,同時也帶來新的能力,讓你思考如何以不同方式管理某個疾病狀態。
On the orders front, Jay, I don't know what else you may want to add?
在訂單方面,Jay,我不知道你還想補充什麼?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
No, overall, like I said earlier, pleased with orders in the second quarter. I think for us that getting to that mid-single digit really does unlock the long-term model that we have. What I would say, I don't want to unpack too much beneath what we've shared for competitive reasons. But what I would say is, generally, we saw strength across geographies, which was great. And the 6% did include the very strong PDx number in it. So if we were to look for a more traditional line equipment type businesses, the orders growth was 4%. You could do that math but I think it gives an illustration as to the health of the equipment businesses that we have, which is solid.
沒有,整體而言,就像我先前說的,我對第二季的訂單表現感到滿意。我認為對我們來說,達到中個位數成長確實能解鎖我們的長期模型。我想說的是,基於競爭因素,我不想把我們已分享內容之下的細節拆解太多。但我會說,一般而言,我們看到各地區都有強勁表現,這很棒。而 6% 的數字也包含了非常強勁的 PDx 表現。因此,如果我們看更傳統的直線型設備業務,訂單成長是 4%。你可以自己算一下,但我認為這能說明我們設備業務的健康狀況——是穩健的。
Operator
Operator
And our next question coming from the line of Suraj Kalia with Oppenheimer.
下一個問題來自 Oppenheimer 的 Suraj Kalia。
Suraj Kalia - MD & Senior Analyst
Suraj Kalia - MD & Senior Analyst
Pete, can you hear me all right?
Pete,你聽得到我嗎?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes.
聽得到。
Suraj Kalia - MD & Senior Analyst
Suraj Kalia - MD & Senior Analyst
Perfect. Jay, it's a pleasure to be working with you again. Welcome to GE HealthCare. So 1 question for Pete and 1 for Jay. Jay, I'll start out with you. Corporate margin is a little over 40%. Obviously, you've laid out a road map in terms of rationalizing TSAs, IT, product SKUs. Can you walk us through how should we think about corporate gross margins, let's say, over the next 4, 6, 8 quarters? What are the key things that we should be looking for? That's 1 question for Jay.
太好了。Jay,很高興再次與你合作。歡迎加入 GE HealthCare。我有 1 個問題問 Pete、1 個問題問 Jay。Jay,我先問你。公司層級毛利率略高於 40%。顯然,你已經提出一個路線圖,包含精簡 TSA、IT、產品 SKU。你能帶我們走一遍,未來 4、6、8 個季度我們應該如何看待公司毛利率?有哪些關鍵事項是我們應該關注的?這是給 Jay 的第一個問題。
And Pete, if I could just quickly throw in a question for you, piggybacking on the AI question. I have a more higher level question, Pete. So obviously, you'll have a lot of AI/ML in your systems. Over time, how do you envision exogenous AI systems interacting with your system AIs? Do you ultimately believe this is going to be synergistic? Do you anticipate disruption? How do you hold pricing, whether it's ChatGPT or whatever but I'm more interested on the exogenous influences as you'll try to grow and maintain your AI services business?
Pete,如果我可以再快速補一個問題給你,延續 AI 的問題。我有一個更高層次的問題,Pete。很明顯,你們的系統會有很多 AI/ML。隨著時間推進,你如何想像外部(exogenous)的 AI 系統會如何與你們系統內的 AI 互動?你最終認為這會是協同效應嗎?你預期會有顛覆嗎?你如何維持定價——不論是 ChatGPT 或其他——但我更關心的是外部影響,因為你們將努力成長並維持你們的 AI 服務業務?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Do you want to start with gross margin, Jay?
Jay,你要先從毛利率開始嗎?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. So overall, in the second quarter, gross margin was up, mainly driven by price and productivity, which offset inflation. And I know that wasn't your question but I share that because fundamental to our algorithm going forward is price and productivity offsetting inflation, along with the benefits of new products. So for us, this is an intense -- this idea of securing a 2% to 3% price in this year's numbers, securing 1% to 2% going forward, that's a crucial enabler when coupled with a lot of the productivity initiatives that we have ongoing at the company.
當然。整體而言,第二季毛利率上升,主要由價格與生產力驅動,抵銷了通膨。我知道那不是你的問題,但我分享這點是因為,未來我們演算法的根本在於:價格與生產力抵銷通膨,再加上新產品帶來的效益。對我們來說,這是一個很強力的——在今年數字中確保 2% 到 3% 的價格提升、未來持續確保 1% 到 2%,在與公司正在推動的多項生產力計畫結合時,是一個關鍵的促成因素。
So I'll stop short of giving a -- of giving the 2024 gross margin number. But what I can say is, there will be a lot of the benefits of TSA and G&A optimization that obviously accrue to the SG&A line. But we do expect gross margin enhancements going forward, largely based on price plus new products, plus some of this work that we're doing on productivity initiatives. Now as we think about the next couple of quarters, what I would say, generally speaking is, the third quarter will probably be in the range of the second quarter, with the fourth quarter being the highest of the year and a lot of that just has to do with seasonality benefits as is normally the case. But then as we move to next year, we'll have that discussion in the future.
所以我先不給出——不給出 2024 年毛利率的數字。但我能說的是,TSA 與 G&A 最佳化的許多效益,顯然會反映在 SG&A 這一行。不過,我們確實預期未來毛利率會提升,主要基於價格加上新產品,再加上我們在生產力計畫上所做的一些工作。至於接下來幾個季度,我一般會說,第三季大概會落在與第二季相近的區間,而第四季會是全年最高,這很大一部分只是因為季節性效益,一如往常。但等我們進入明年,我們之後再討論。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
And on your question about AI, exogenous impacts and such, look, I think the key here is that our first level of AI that we have out right now, which, again, because of the combination of software upgrades and the value it brings, are bringing significantly higher margins into our sales when those are incorporated. I think an upgrade in an MRI unit relative to Air Recon DL can have margin contribution that can rival a larger system. And I think that mix change over time is going to impact our broader products.
至於你關於 AI、外部影響等的問題,聽著,我認為關鍵在於:我們目前推出的第一層 AI——再說一次,因為軟體升級與其帶來的價值相結合——在納入銷售時,正帶來顯著更高的利潤率。我認為,相較於 Air Recon DL,對 MRI 設備進行升級,其毛利貢獻可以媲美一套更大型的系統。我認為,隨著時間推移,這種組合變化將影響我們更廣泛的產品。
To your point, most of our AI today is incorporated in our own proprietary Recon data. So it's kind of our domain. And as we go beyond that, we look at, say, how we're going to build this within this ecosystem and really embrace some of these technologies. The key is, to always be the face to the customer which, again, is one of our strong parts with our reach and be really trusted as someone that can help a customer navigate this ecosystem.
如你所說,我們今天的大多數 AI 都整合在我們自有的專有 Recon 資料中,所以這算是我們的領域。而當我們超越這一點時,我們會看,例如,我們要如何在這個生態系中建構並真正擁抱其中一些技術。關鍵是,始終要成為面向客戶的那一方;再說一次,憑藉我們的觸及範圍,這是我們的強項之一;並且成為真正值得信賴、能協助客戶在這個生態系中前行的人。
If you think about cybersecurity, which we've been focused on for many, many years with so many different products that are out there, the privacy of the data and really having kind of the right committees we're bringing together, we think about ethics and health care about how these come together, I think that's at its core. One of the key reasons I wanted Taha to come in as our Chief Technology Officer, his background as interventional cardiologist, worked at the FDA on data statistics and then 7 years at Amazon leading AI and ML is exactly this, is to be able to distill through and look at the right partnerships that we want to leverage because of our position.
如果你想到資安——我們多年來一直專注於此,面對市面上如此多不同的產品——資料隱私,以及真正建立起我們正在召集的合適委員會;我們也會思考倫理與醫療照護如何結合在一起,我認為這是核心。我之所以希望 Taha 來擔任我們的技術長,其中一個關鍵原因就在於此:他具備介入性心臟科醫師背景,曾在 FDA 從事資料統計工作,之後在 Amazon 領導 AI 與 ML 七年,正是為了能夠梳理、判斷並選擇我們希望運用的正確合作夥伴,基於我們的定位。
I think you probably know, about half of the data created in health care, we either are directly creating and are a part of it just based on the amount of 4K plus data that's generated out of the imaging world. And with our integration and building platforms that can enable third parties but also create an ecosystem where for customers, this is the place you want to go to kind of leverage connectivity but also integrated AI apps, this is at the core of what we're focused on.
我想你可能知道,醫療照護所產生的資料大約有一半,我們要嘛是直接在產生、要嘛就是其中的一部分,這取決於影像領域所生成的大量 4K+ 資料。透過我們的整合與平台建置,既能讓第三方啟用,也能打造一個生態系,讓客戶覺得這裡就是你想來的地方——用來運用連結性,也用來運用整合式 AI 應用——這正是我們專注的核心。
And so I would say, standby, I think later this year, we'll be able to talk more about what our plans are and demonstrations around it. But this is an important part of it. We view it less as a threat, as more of how do we embrace it and give a door into health care as someone that really knows our customers well, understand their cyber concerns or security concerns and really helps think about how to solve their problems the right way.
所以我會說,請拭目以待。我想在今年稍晚,我們將能更進一步談我們的計畫,以及相關展示。但這是其中很重要的一部分。我們較少把它視為威脅,而更多是在想:我們要如何擁抱它,並以真正了解客戶、理解他們的資安或安全疑慮的人之姿,成為進入醫療照護的一扇門,並真正協助以正確方式解決他們的問題。
One of the interesting things that's out there today is, there's a lot of AI applications for diagnosis. But if they aren't integrated in the disease pathway the appropriate way, they actually add work and complexity. One of our expertise is, how do you integrate them into your workflow so you get the benefit for the patient but you also get the productivity for the system. And that's really where we add a lot of value.
目前有一件很有意思的事是,市面上有很多用於診斷的 AI 應用。但如果它們沒有以適當的方式整合進疾病照護路徑,反而會增加工作量與複雜度。我們的專長之一,就是如何把它們整合到你的工作流程中,讓病人獲益,同時也讓系統提升生產力。而這正是我們能創造大量價值的地方。
Operator
Operator
And our next question coming from the line of Vijay Kumar with Evercore ISI.
下一個問題來自 Evercore ISI 的 Vijay Kumar。
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Congrats on the nice (inaudible) here. Pete, my first question for you. One of your competitors called out order declines, Russia headwinds. So when you look at your book-to-bill of 1.04x, was that a clean number? Was there a Russia headwind? I'm wondering what that number ex Russia headwind was? And when you think about your order growth versus your peer seeing declines, is that sort of signaling some share shifts in the industry?
恭喜你們這次表現不錯(聽不清)。Pete,我第一個問題想請教你。你們的一位競爭對手提到訂單下滑、俄羅斯帶來的逆風。所以當你看你們的 book-to-bill 為 1.04 倍時,這個數字是「乾淨」的嗎?是否有俄羅斯逆風的影響?我想知道若排除俄羅斯逆風,這個數字會是多少?另外,當你們的訂單成長、而同業卻看到下滑時,這是否在暗示產業內出現了一些市占轉移?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes. Look, I would say, from a standpoint of overall market and share, our philosophy has been really balanced on getting the most value for our products in all the geographies and also balancing share. An ideal scenario for us is to hold or be slightly up in share but to be able to get the right value in all the geographies. And again, this ties back to price, gross margin, all the kind of things. That's what we've been focused on. But we have done reasonably well here in the last 9, 12 months. And some of that is directly attributed to our metric we use, which is NPI vitality, which is new products generating sales. I mentioned monitoring, yet a big contributor but when you haven't had a new platform in over a decade and you bring that out, there's just a really nice installed base opportunity. And because it's more of a cutting-edge opportunity, you also have an opportunity to go into others installed base and say, "Hey, maybe you should take a look at us."
是的。你看,從整體市場與市占的角度來說,我們的理念一直是很平衡:在所有地理區域為我們的產品取得最大的價值,同時也兼顧市占。對我們而言,理想情境是市占持平或小幅上升,但同時能在各個地區取得合理的價值。再說一次,這會回扣到價格、毛利率等各種因素——這就是我們一直專注的重點。不過在過去 9 到 12 個月,我們確實做得相當不錯。其中一部分可直接歸因於我們使用的一個指標,也就是 NPI vitality(新產品帶來的銷售活力)。我提到監護(monitoring)仍是很大的貢獻者,但當你超過十年都沒有推出新平台、而你把它推出來時,就會有非常好的既有裝機基礎(installed base)機會。而且因為這更偏向前沿機會,你也有機會切入其他人的裝機基礎並說:「嘿,也許你應該看看我們。」
So I think we're in a good position from that standpoint. Look, from the Russia point of view, we've been focused on the humanitarian support that has been supported by governments around the world. From a standpoint of call out, we didn't believe there's anything to call out because we've actually contemplated it in our overall guidance. And I would say, in the second half, as I said, it's in there. If things drastically improve, maybe we could do a little bit better against that. But we've been factoring that in all along about what was taking place. The added process controls and things that the U.S. government had put in place, I think the team has managed reasonably well but it's clearly had more of a extending the time to have a transaction take place. But again, just to reinforce, it's contemplated in our guidance.
所以我認為從這個角度我們處於不錯的位置。至於俄羅斯方面,我們一直專注於由全球各國政府所支持的人道援助。就需要特別點出(call out)的角度而言,我們不認為有什麼需要特別點出,因為我們其實已經把它納入整體財測指引中。我會說,在下半年,如我所說,已經包含在內了。如果情況大幅改善,也許我們能比目前預期做得稍微好一些。但我們一路以來都把正在發生的事情納入考量。美國政府所加上的額外流程管制等,我認為團隊管理得還算不錯,但顯然它讓交易完成所需的時間拉長了。不過再次強調,這些都已經反映在我們的指引中。
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
And just to clarify that, Pete, how big is Russia for GE HealthCare? And what are then the declines in Russia, if at all, in 2Q?
再釐清一下,Pete,俄羅斯對 GE HealthCare 來說有多大?那麼在第二季,俄羅斯的下滑幅度(如果有的話)是多少?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
So we basically -- we don't break that fully out. But Russia, as we've said in the past, is 2% or slightly below that in that range is what it represents for us.
我們基本上——不會把那部分完全拆開揭露。但如同我們過去所說,俄羅斯約占我們 2% 或略低於 2%,大概就是這個區間。
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
And the decline in 2Q?
那第二季的下滑呢?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
No, no. The total Russia business is roughly 2%, maybe slightly below that in sales that it represents against the whole company.
不,不。俄羅斯整體業務大約占 2%,可能略低於 2%,以銷售額來看相對於全公司就是這個比重。
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Understood. And Jay, maybe 1 quick one for you. Your back half margins, I think there's a 200-basis point step up versus first half. Looking at 2Q, it seems like OpEx came in slightly above. Maybe just talk about visibility in the back half margin step up?
了解。Jay,再問你一個很快的問題。你們下半年毛利率/利潤率,我想相較上半年大概有 200 個基點的跳升。看第二季,似乎營業費用(OpEx)略高一些。能否談談對下半年利潤率跳升的能見度?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Yes. I think in the second quarter, it was an important improvement from the first quarter. We saw 70 basis points of margin expansion. And what I'd like to see, Vijay, is we did that in the face of fairly substantial R&D growth, which is great as we look to accelerate some of the new products that we have and some of the excitement there. So 70 basis points improvement from Q1 to Q2. As we move to the second half of the year, what I would say is, the third quarter is probably going to be along the lines of the second quarter from an overall margin standpoint. We always do have a substantial tick up in the fourth quarter and we will start to see some of the benefits from some of the activities on G&A impacting the fourth quarter. So you start to see a little bit of that impact coming through. And that's what really drives up the fourth quarter to a much higher level than we've seen earlier in the year.
是的。我認為第二季相較第一季是一次重要的改善。我們看到利潤率擴張了 70 個基點。Vijay,我希望你注意到的是,我們是在研發(R&D)相當顯著成長的情況下做到這點的;這很好,因為我們希望加速一些新產品以及相關的市場熱度。所以從 Q1 到 Q2 改善了 70 個基點。展望下半年,我會說第三季從整體利潤率角度來看,大概會與第二季相近。我們第四季一向會有明顯的上升,而我們也會開始看到部分一般與管理費用(G&A)相關活動在第四季帶來的效益,所以你會開始看到一些影響逐步顯現。這也正是推動第四季利潤率升到遠高於今年前幾季水準的主要原因。
And I think that's also important because it does set the stage as we move into 2024 for continued margin expansion. So I think we feel good about line of sight. We're watching things obviously very cautiously as we always are. But we have good line of sight to the margin expansion that we've laid out. And like I say, importantly, we saw a nice second quarter and a nice imaging margin growth from Q1 to Q2, which are key enablers for us long term.
我認為這也很重要,因為它為我們邁入 2024 年、持續擴大利潤率奠定了基礎。所以我們對可視性(line of sight)感到不錯。我們當然會像一貫那樣非常謹慎地觀察各項情況。但對於我們所提出的利潤率擴張路徑,我們有良好的可視性。而且如我所說,重要的是,我們在第二季表現不錯,影像業務(imaging)的利潤率也從 Q1 到 Q2 有不錯的成長,這些都是我們長期的關鍵推動因素。
Operator
Operator
And our next question coming from the line of Yuan Zhi with B. Riley.
下一個問題來自 B. Riley 的 Yuan Zhi。
Yuan Zhi - Research Analyst of Healthcare
Yuan Zhi - Research Analyst of Healthcare
Congrats on the strong quarter of PDx. Great to see your presence as the Nuclear Medicine Conference in Chicago. Can you provide more details on the manufacturing capacity for Vizamyl? Can you clarify how the manufacturing is contracted with manufacturing network at the moment? In other words, if there is surge in demand of this imaging agent for Alzheimer's disease, how will you adapt to that quickly?
恭喜 PDx 這一季表現強勁。也很高興在芝加哥的核子醫學會議看到你們的參與。你能否提供更多關於 Vizamyl 的製造產能細節?也請釐清目前製造是如何與製造網路簽約合作的?換句話說,如果這個用於阿茲海默症的顯影劑需求突然激增,你們將如何快速因應?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes. No, great question. So as -- again, your question is about Vizamyl, which is the radiopharmaceutical that is used and approved. It's 1 of 3 out there but it's the only one that actually is approved for color interpretation, meaning that you get a highlight film that actually shows a heat map, which we believe aids in the ability to kind of quantify and diagnose.
是的,這是個好問題。你的問題是關於 Vizamyl,也就是已被使用並獲核准的放射性藥物。市面上大概有 3 種,但它是唯一一個核准可進行彩色判讀的,意思是你會得到一張高亮度的影像膠片,實際呈現熱度圖(heat map),我們相信這有助於量化與診斷的能力。
As it is a radiopharmaceutical, you actually have to have a location where there's a cyclotron and which we manufacture. As well as what's called FASTlab, which is kind of a synthesis cassette-based structure, which enables fast conversion to make the product. So we offer all of those. We have our own sites and then we have a network of partners. I would just say from what we've seen as early indications of what the uptake would be, we believe we have added capacity -- adequate capacity to ramp up to meet the needs. Pending on how successful molecule 1, molecule 2 and potentially future molecules will be, we can actually ramp up capacity with our network and our own investment.
由於它是放射性藥物,你必須有一個具備迴旋加速器(cyclotron)的地點來進行製造,而這部分我們有生產。同時還需要所謂的 FASTlab,這是一種以合成匣(cassette)為基礎的架構,可讓製程快速轉換以製成產品。我們提供上述所有項目。我們有自有據點,也有合作夥伴網路。就我們目前看到的、對採用率(uptake)的初步跡象而言,我們相信我們已增加產能——具備足夠的產能可擴產以滿足需求。視分子 1、分子 2 以及未來可能的分子成功程度而定,我們也可以透過合作網路與自有投資來進一步擴充產能。
So I don't see that being any type of a near-term issue for us. And again, as I had mentioned earlier, we're just really excited for patients and their families and what this opportunity means. But it's a critical point here that be able to actually have baseline visualization to see what the plaque quantification of amyloid beta is. And then after -- while doing the treatment, be able to have MRI to monitor exactly how that patient is doing. And then we suspect further along being able to actually see what reduction in plaque took place later on in follow-up.
所以我不認為這會在短期內成為我們的問題。再者,如我先前提到的,我們對病人及其家屬、以及這個機會所代表的意義感到非常振奮。但這裡有一個關鍵點:必須能夠進行基線視覺化(baseline visualization),以看到 β 類澱粉蛋白(amyloid beta)斑塊的量化情況。接著在治療期間,能用 MRI 監測病人的狀況到底如何。然後我們推測在更後期的追蹤中,還能實際看到斑塊減少的幅度。
So a big part of this, I think you know, is going to be the reimbursement out of CMS. We were encouraged that the one kind of Alzheimer's scan per lifetime CMS indication. They came back and said that they're looking to move that towards the MACs to make that decision. We hope that, that moves to a national coverage decision but the fact that it moved to the MACs to actually look at, it is encouraging step in the right direction. So we feel like we're in pretty good shape based on what the demand curves will look like to meet the needs.
所以我想其中很大一部分,會取決於 CMS 的給付(reimbursement)。我們對 CMS 所提出的「每位受益人一生一次」阿茲海默症掃描指引感到鼓舞。他們回覆表示,正考慮把決策下放到 MACs 來做。我們希望這能走向全國性給付決定(national coverage decision),但能先移交給 MACs 來評估,本身就是朝正確方向邁進、令人鼓舞的一步。因此,基於我們對需求曲線可能樣貌的判斷,我們覺得在滿足需求方面狀況相當不錯。
Operator
Operator
And our last question in queue coming from the line of Jason Bednar with Piper Sandler.
我們佇列中的最後一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - Director & Senior Research Analyst
Jason M. Bednar - Director & Senior Research Analyst
Congrats on another nice quarter here. Wanted to start on PDx, that segment just put up again another quarter of really strong results. Understanding comps in the second half are a little bit tougher than the first half. You called out some of the factors influencing that situation. But I guess, is it right to think the absolute revenue run rate up here around $550 million to $575 million. Is that the correct baseline for PDx now moving forward? And then are there any notable geographic trends you'd call out when we look at that PDx strength?
恭喜又交出一個不錯的季度表現。我想先從 PDx 開始談起,該部門又繳出一個非常強勁的季度成績。了解下半年相較於上半年,基期比較會更具挑戰性。你們也點出了影響這種情況的一些因素。但我想確認一下,是否可以把目前大約 5.5 億到 5.75 億美元的絕對營收運行水準,視為 PDx 未來的正確基準?另外,從 PDx 的強勢表現來看,有沒有任何值得一提的地理區域趨勢?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Go ahead, Jay.
請說,Jay。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. On PDx, we did have a shutdown in the second quarter of our manufacturing facility in China related to COVID and that reopened in the third -- there was a -- it reopened towards the end of the second quarter, into the third quarter. So we did -- we have a very challenging comp in the third quarter. That's what everybody is referring to. And so what I would say is, from a total dollar standpoint, yes, I think that we're -- that's the right range in terms of overall sales. But the growth rates will look a bit distorted by some of those comparator issues, as we look at last year. But I think your comment is a good one. I mean this is a great business for us. We're pleased with the growth that we've seen and this will be an important driver, also as it relates to the last question as well. So this is a nice source of growth for us.
好的。關於 PDx,我們第二季在中國的製造工廠因 COVID 停工,並在第三季重新開工——它是在第二季末、進入第三季時恢復運作。因此,我們在第三季面臨非常具挑戰性的比較基期,大家指的就是這點。所以我會說,從總金額的角度來看,是的,我認為整體銷售額落在那個區間是合理的。但由於與去年相比的比較基期問題,成長率看起來會有些失真。不過我認為你的評論很到位。這對我們來說是一個很棒的業務。我們對目前看到的成長感到滿意,而且這也會是一個重要的驅動因素,與上一個問題也有關聯。所以這是我們一個不錯的成長來源。
I don't know, Pete, if you'd add anything?
我不知道,Pete,你要不要補充?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes. No, just the fact that if you think of our PDx business, it's fundamentally about a 70-30 contrast agent imaging business and 30% molecular imaging. And obviously, the more molecular imaging grows over time, whether it be theranostics or Alzheimer's, other things I had mentioned about FES PET getting into metastatic breast cancer, that's going to grow with even higher margins than the traditional side of the house.
是的。不,主要是如果你看我們的 PDx 業務,本質上大約是 70/30 的對比劑影像業務,以及 30% 的分子影像。很明顯地,隨著時間推進,分子影像不論是治療診斷一體化(theranostics)或阿茲海默症等領域的成長——以及我提到的其他事項,例如 FES PET 進入轉移性乳癌——都將以比傳統業務更高的毛利率成長。
That being said, you really can't do a vascular study without contrast. Obviously, without the agents there's actually limited capacity throughout the world. And we've -- as we've talked about as well, committed to making the proper investments to shore up supply in the [respectable] markets. But, to Jay's point, it will be a little lumpy here over the next couple of quarters because of the shutdown we had in Q2 last year but we feel quite good about it. Think about all the surge in procedures that are taking place, for interventional procedures in cardiac, many of the different procedures that are happening that you're seeing for other implantable devices. In many cases, there is a study that involves a with or without contrast study to get them there and that's one of the underlying drivers in the marketplace.
話雖如此,你確實無法在沒有對比劑的情況下進行血管研究。顯然,若沒有這些藥劑,全球其實存在供應能力受限的情況。而且我們——如同我們也談到的——已承諾進行適當投資,以強化在這些[respectable]市場的供應。但如 Jay 所說,接下來幾個季度會有些起伏,因為去年第二季的停工所致,但我們對此相當有信心。想想目前各種手術量的激增,例如心臟介入手術,以及你在其他植入式裝置所看到的許多不同手術。在很多情況下,會有一項包含使用或不使用對比劑的檢查來引導流程,而這正是市場上的其中一個底層驅動因素。
Jason M. Bednar - Director & Senior Research Analyst
Jason M. Bednar - Director & Senior Research Analyst
All right. Very helpful, guys. And then maybe just as a follow-up for Jay. I appreciate all the color on gross margins here today in terms of modeling forward and the various impacts. I want to drill down maybe a bit more on imaging gross margin. You called out inflation from past component purchases as a factor and it's totally understandable here, just as everybody is dealing with the inflationary effects. And then as you prepare with your balance and your inventory and whatnot. But as you look at your backlog and where you're at with imaging product inventory, are we past the worst of those component inflation headwinds?
好的。非常有幫助,各位。接著也許作為對 Jay 的追問:我很感謝你今天就毛利率、包含前瞻建模與各種影響因素所提供的詳細說明。我想再更深入一點談影像業務的毛利率。你提到過去採購的零組件帶來的通膨是其中一個因素,這完全可以理解,畢竟大家都在面對通膨效應,以及你們在資產負債表與庫存等方面的準備。但當你看你們的訂單積壓(backlog)以及影像產品庫存的狀況時,我們是否已經度過那些零組件通膨逆風最糟的階段?
And then along those lines, could you offer maybe some comments or your level of comfort around seeing imaging segment margins improve further in the second half from where we finished in 2Q?
另外沿著這個方向,你能否談談你對影像部門毛利率在下半年、相較於我們在第二季結束時的水準,進一步改善的看法或信心程度?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. So really a nice performance in the second quarter on imaging. I think that entire team is incredibly focused on margin enhancements and gross margin, in particular, along with pricing and productivity improvement. So I think that's a -- it was a great enhancement from the 7.7% to 10.6%. We do expect the second half of the year to be above the first half for imaging. And a lot of that does come down to some of these inflation purchases that we've had in the second half of last year, they do start to lessen from an impact standpoint. And frankly, this is our longest lead time business. And so we do see -- that's why it's kind of lingered for the longest period of time. But we'll start to see that ease in the second half of the year. So that will be another incremental tailwind for imaging margins. So you can expect to see, like I say, second half above first half, hopefully setting the stage for a nice 2024.
當然。影像業務在第二季的表現確實不錯。我認為整個團隊都非常專注於提升利潤率,尤其是毛利率,同時也著重於定價與生產力改善。所以我認為這是——從 7.7% 提升到 10.6% 是很大的改善。我們確實預期今年下半年影像業務會高於上半年。而其中很大一部分,來自於我們去年下半年所做的一些通膨性採購,其影響會開始減弱。坦白說,這是我們交期最長的業務,因此我們確實看到——這也是為什麼它拖得最久。但我們會在今年下半年開始看到壓力緩解。因此,這也會成為影像毛利率的另一個增量順風。總之,你可以預期如我所說,下半年高於上半年,希望也能為 2024 年打下良好基礎。
Operator
Operator
Thank you, ladies and gentlemen. I will now turn the call back over to Mr. Arduini for any closing remarks.
謝謝各位女士先生。現在我將把電話會議交回給 Arduini 先生,請他做任何結語。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
So thank you for joining us today. And look, we're excited about the significant opportunities ahead as we work to help transform the future of health care and focus on the enablement of precision care. We look forward to connecting you at one of our upcoming conferences. Thanks for your time today.
感謝各位今天加入我們。你看,當我們致力於協助推動醫療保健的未來轉型,並聚焦於促進精準照護的落實時,我們對前方重大的機會感到振奮。我們期待在即將到來的某場會議上與各位交流。感謝各位今天撥冗參與。
Operator
Operator
Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation. You may now disconnect.
各位女士先生,今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。